PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas (Q38996724)

8 September 2017

1 reference

title

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas (English)

1 reference

8 September 2017

3

Razelle Kurzrock

1 reference

8 September 2017

Aaron Goodman

1

1 reference

8 September 2017

Sandip P Patel

series ordinal

2

1 reference

8 September 2017

language of work or name

English

0 references

publication date

2 November 2016

1 reference

Nature Reviews Clinical Oncology

8 September 2017

published in

1 reference

8 September 2017

volume

14

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

203-220

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

CTLA-4 ligation blocks CD28-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The role of B7 family molecules in hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Molecular mechanisms of T cell co-stimulation and co-inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Targetable genetic features of primary testicular and primary central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

How I treat advanced classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Review of the cardiac long-term effects of therapy for Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Structural genomic alterations in primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The molecular pathogenesis of primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Follicular helper CD4 T cells (TFH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

How I treat HIV-associated lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

How I treat HIV-associated multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Update on the treatment of HIV-associated hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Diagnosis and management of lymphomas and other cancers in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Inadequate T follicular cell help impairs B cell immunity during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Follicular lymphoma: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Lenalidomide enhances anti-myeloma cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Immunotherapy: Study deciphers enigmatic mechanism of PD-L1 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Genetic and Epigenetic Regulation of PD-1 Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4+ T cells in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Gains ofREL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

How I treat patients with diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Love the one you're with: the HIV, B cell and TFH cell triangle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.168

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

31 March 2020

1 reference

12 December 2020

Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells

1 reference

12 December 2020

Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection.

1 reference

12 December 2020

Bcl-2 initiates a new category of oncogenes: regulators of cell death

1 reference

12 December 2020

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

1 reference

12 December 2020

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

10.1038/NRCLINONC.2016.168

Identifiers

DOI

1 reference

8 September 2017

1 reference